Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial

Haematologica

Volumn 100, Issue 9, 2015, Pages 1207-1213

  García Sanz, Ramón ^a   Oriol, Albert ^b   Moreno, María J ^c   De La Rubia, Javier ^d   Payer, Angel R ^e   Hernández, Miguel T ^f   Palomera, Luis ^g   Teruel, Ana I ^h   Blanchard, María J ⁱ   Gironella, Mercedes ^j   Ribas, Paz ^k   Bargay, Joan ^l   Abellá, Eugenia ^m   Granell, Miquel ⁿ   Ocio, Enrique M ^a   Ribera, Josep M ^b   San Miguel, Jesús F ^o   Mateos, María V ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e Central de Asturias   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^h UNIVERSITY OF VALENCIA   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^l HOSPITAL SON LLÀTZER   (Spain)

^m HOSPITAL DEL MAR   (Spain)

ⁿ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^o UNIVERSITY CLINIC OF NAVARRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

AGED; ANEMIA; ANGINA PECTORIS; AORTA DISEASE; ARTICLE; BIOCHEMICAL RECURRENCE; BONE DISEASE; BONE PAIN; COMMON BILE DUCT STONE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; ISCHEMIA; JAW OSTEONECROSIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUROPATHY; PHASE 4 CLINICAL TRIAL; PLASMACYTOMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RETINA DETACHMENT; SCHOOL CHILD; ADULT; BONE DISEASES; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; BONE DISEASES; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; HUMANS; IMIDAZOLES; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL RATE;

EID: 84940916203     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.128439     Document Type: Article

References (33)

1. Mateos M-V, San Miguel JF. How should we treat newly diagnosed multiple myeloma patients? Hematology Am Soc Hematol Educ Program. 2013;2013:488-495
2. Durie BG, Harousseau JL, Miguel JS, et al International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-1473
3. Rajkumar SV, Harousseau JL, Durie B, et al Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18): 4691-4695
4. Terpos E, Morgan G, Dimopoulos MA, et al International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease. J Clin Oncol. 2013;31(18):2347-2357
5. Croucher PI, De Hendrik R, Perry MJ, et al Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18(3):482-492
6. Corso A, Ferretti E, Lunghi M, et al Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer. 2005;104(1): 118-125
7. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997;98(3):665-672
8. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007;24(2):227-230
9. Morgan GJ, Davies FE, Gregory WM, et al First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376 (9757):1989-1999
10. Berenson JR, Lichtenstein A, Porter L, et al Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2):593-602
11. Caparrotti G, Catalano L, Feo C, Vallone R, Pagnini D, Rotoli B. Perspective study on pamidronate in stage I multiple myeloma Hematol J. 2003;4(6):459-460
12. Martin A, Garcia-Sanz R, Hernandez J, et al Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol. 2002;118(1):239-242
13. Martini G, Gozzetti A, Gennari L, Avanzati A, Nuti R, Lauria F. The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. Haematologica. 2006;91 (12):1720-1721
14. Musto P, Falcone A, Sanpaolo G, et al Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma 2003;44(9):1545-1548
15. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma Cancer. 2008;113(7):1588-1595
16. D'Arena G, Gobbi PG, Broglia C, et al Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma. 2011;52(5):771-775
17. Garcia-Sanz R, Alegre A, Capote FJ, et al [Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group]. Med Clin (Barc). 2010;134(6):268-278
18. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Ann Oncol. 2009;20(8):1303-1317
19. Raje N, Anderson KC. Introduction: the evolving role of bisphosphonate therapy in multiple myeloma. Blood. 2000;96(2):381-383
20. Locke FL, Morgan GJ. What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease? Hematology Am Soc Hematol Educ Program. 2012;2012:350-353
21. Gnant M, Clezardin P. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev. 2012;38(5):407-415
22. Berenson JR, Lichtenstein A, Porter L, et al Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group New Engl J Med. 1996;334(8):488-493
23. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96(2):384-392
24. Kyle RA, Durie BG, Rajkumar SV, et al Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-1127
25. Dimopoulos M, Kyle R, Fermand JP, et al Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18): 4701-4705
26. Zamarin D, Giralt S, Landau H, et al Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation Bone Marrow Transplant 2013;48(3):419-424
27. Fernandez de Larrea C, Jimenez R, Rosinol L, et al. Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplant. 2014;49(2):223-227
28. Mateos MV, Richardson PG, Schlag R, et al Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259-2266
29. Garcia-Sanz R, Mateos MV, San Miguel JF [Multiple myeloma]. Med Clin (Barc) 2007;129(3):104-115
30. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110(8):1860-1867
31. Sonmez M, Akagun T, Topbas M, et al Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res. 2008;27:11
32. Delea T, McKiernan J, Brandman J, et al Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006;4(7):341-347
33. Groot MT, Huijgens PC, Wijermans PJ, Uylde Groot CA. Costs of multiple myeloma and associated skeletal-related events in the Netherlands. Expert Rev Pharmacoecon Outcomes Res. 2004;4(5):565-572